Biogen (BIIB) PT Raised to $320 at Barclays

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. LITE
2. CRWD
3. REGN
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. ORCL

Go back to Biogen (BIIB) PT Raised to $320 at Barclays

Biogen (BIIB), Eisai Highlight Detailed Results from Phase II Clinical Study of Elenbecestat at AAIC 2018

July 25, 2018 10:38 AM EDT

Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimers Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. This poster presentation was accepted as a Late Breaking Abstract for AAIC (Poster No.: P4-389).

Study 202 (ClinicalTrials.gov identifier NCT02322021) is a multicenter, randomized, double-blind, placebo-controlled parallel-group 18-month Phase II clinical study, conducted in the United States in patients with... More

Biogen (BIIB) PT Raised to $392 at Morgan Stanley

July 25, 2018 7:46 AM EDT

Morgan Stanley raised its price target on Biogen (NASDAQ: BIIB) to $392.00 (from $366.00) while maintaining a Overweight rating.

... More

Biogen (BIIB) PT Raised to $357 at RBC Capital

July 25, 2018 7:44 AM EDT

RBC Capital raised its price target on Biogen (NASDAQ: BIIB) to $357.00 (from $349.00) while maintaining a Sector Perform rating.

Analyst Brian Abraham said the solid quarter with guidance raise should help keep enthusiasm high for BIIB following recent de-risking of key Alzheimer's portfolio.

... More

Biogen (BIIB) PT Raised to $348 at Baird

July 25, 2018 6:40 AM EDT

Baird raised its price target on Biogen (NASDAQ: BIIB) to $348.00 (from $323.00) while maintaining a Neutral rating.

Analyst Brian Skorney commented, "Biogen reported in-line revenues of $3.4B and EPS of $5.80, beating consensus at $5.21. A return for growth for Spinraza and solid performance... More

Biogen (BIIB) PT Raised to $445 at JPMorgan

July 24, 2018 1:55 PM EDT

JPMorgan raised its price target on Biogen (NASDAQ: BIIB) to $445.00 (from $400.00) while maintaining a Overweight rating.

Analyst Cory Kasimov remains positive on the company following a strong beat and raise in Q2. The analyst notes the resilience of the core portfolio and... More

Biogen (BIIB) Tops Q2 EPS by 56c, FY Guidance Tops Consensus

July 24, 2018 6:37 AM EDT

(Updated - July 24, 2018 6:39 AM EDT)

Biogen (NASDAQ: BIIB) reported Q2 EPS of $5.80, $0.56 better than the analyst estimate of $5.24. Revenue for the quarter came in at $3.36 billion versus the consensus estimate of $3.26 billion.

GUIDANCE:

Biogen sees FY EPS of $24.90-$25.50 vs... More